German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.
1 report, 1 independent
Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
German drug pricing policy creates investment risk for pharmaceutical companies, including AstraZeneca and Boehringer Ingelheim.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.
-
Boehringer Ingelheim
German pharmaceutical company
Nothing else this week.